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Abstract
Nanoparticles (NPs) are included in a variety of consumer products including
cosmetics, food, and food packaging. They are also used in medical products for
dermal and oral application and for inhalation. The thinness of the air–blood barrier,
the large absorption area of the lung, and the relatively low inactivation by enzymes
provide fast entry to the systemic blood circulation at high drug concentrations. In
addition to intended uptake, exposure to airborne particles from the environment and
to NPs released during the manufacturing process may occur. Cytotoxicity is
routinely studied for 4–48 h of exposure, but NPs may accumulate in cells and can
cause cellular effects after longer times. Both extent and consequences of cellular NP
accumulation are currently largely unknown.
In vitro studies could help estimating the extent and the consequences of cellular
accumulation and classify NPs according to their potential to cause adverse effects
upon chronic exposure. Furthermore, such information could help to decrease the
amount of labor- and cost-intensive and ethically problematic animal studies.
Important parameters for representative chronic cytotoxicity testing in vitro include
choice of the appropriate cells and of physiological relevant culture and exposure
conditions, verification of uptake, and identification of cell damage.
Calu-3 bronchial epithelial cells are a suggested cell line for physiologically relevant
testing when cultured on membranes, which allows supplying the cells with nutrients
only from the basal side (culture at an air–liquid interface). This culturing also enables
the exposure to NPs by aerosol. Cytotoxicity can be identified by changes in cell
number, membrane integrity, amount of DNA or protein, and metabolic activity.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
When cells are cultured on membranes and not in plates, measurements of the
transepithelial electrical resistance are a useful indicator for cell damage.
By slight modification of the culture conditions on the membranes, we could maintain
constant transepithelial electrical resistance values of Calu-3 monolayers for 28 days.
Every seven days, cells were exposed to two different doses of fluorescently labeled
20 nm carboxyl-functionalized polystyrene particles either suspended in a small
volume of liquid or by MicroSprayer® IA-1C aerosolizer. It was found that cells
accumulated particles in a linear way over the entire observation time without
apparent cell damage.
The presented system appears suitable for chronic cytotoxicity testing of inhaled NPs
in a physiologically relevant manner.
Keywords: Nanoparticles, Chronic effects, Particle uptake, Particle accumulation,
Cytotoxicity, Respiratory system
1. Introduction
Exposure of humans to nanoparticles (NPs) can occur accidentally by environmental particles
(e.g., air pollution) and intentionally because a variety of consumer products, cosmetics, and
medical products contain NPs. Release of NPs during the manufacturing process may result
in exposure of workers by the dermal, oral, and inhalation route.
Exposure to air pollution, such as ultrafine particles, is known to cause inflammatory airway
diseases and cardiovascular problems in humans [1]. Pope et al. [2] concluded that even low
levels of ambient particle exposure have a significant effect on mortality. The log-linear dose–
response relationship between particles and mortality, which was found in their study,
highlighted the risk upon exposure to relatively low ambient levels.
Less information is available on health risk of inhaled NPs at the workplace. Reported exposure
levels in manufactories for printed electronics, nanoscale metal oxides, and ceramics were low
and below the allowed limits [3-6]. On the other hand, exposure to metal NPs in precious metal
refinery was higher than recommended limits, and mitigating measures were suggested [7].
Adverse effects of respiratory exposure to occupational NPs included allergic symptoms of
the respiratory tract and accumulation in the lung and peritoneum [8-10].
The lung is also one of the suggested routes for noninvasive medication because, compared to
dermal and oral exposure, inhalation provides higher bioavailability of active pharmaceutical
ingredients. The thinness of the air–blood barrier allowing fast entry to the systemic blood
circulation combined with the large absorption area of the lung and the low degree of
inactivation through enzymatic degradation by enterocyte and liver enzymes are the main
reasons for high systemic levels of inhaled drugs. Several NP-based products, such as nano-
salbutamol and nano-fluticasone [11, 12] for chronic obstructive pulmonary disease and
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asthma and nano-atropine sulfate against organophosphorus poisoning [13], successfully
finished testing in healthy volunteers. Furthermore, the safety of heavy chains of Fab fragments
of antibodies produced by Nanobody® technology for respiratory syncytial virus infections
has been demonstrated in a recent phase I trial [14]. Technosphere® (bis-3,6(4-fumarylamino‐
butyl)-2,5-diketopiperazine that adsorbs active pharmaceutical ingredients) insulin has passed
clinical phase II and III trials [15] and is currently being reviewed by the FDA as inhaled
mealtime insulin for managing hyperglycemia in patients with type 1 and type 2 diabetes
mellitus. All applications are intended for longer time periods and raise the issue of potential
adverse effects on the respiratory epithelium upon chronic exposure.
2. Epithelial barriers of the lung
Airborne particles pass the conducting airways (trachea and large bronchi) and the small
bronchi and bronchioli and finally reach the alveoli, where gas exchange takes place. The
surface area of the lung is estimated to be 80–140 m2 large [16]. This large surface is covered
by a small amount of lining fluid, approximately 10–20 ml in total, and separates the environ‐
ment from the systemic blood circulation by only a thin air–blood barrier (0.1–0.2 µm thick).
2.1. Airway lining fluid
The mucus layer covering the trachea and main bronchi is much thinner than the mucus layer
in the oro-gastrointestinal tract. Indications of mucus thickness vary according to the different
techniques that were used for the measurement (Fig. 1). The layer appears to possess a
minimum thickness of 5–10 µm in the large airways, while a thickness of 6.9 µm has been
measured for segmental bronchi [17, 18]. Other data report a constant thickness of 7 µm of the
periciliary layer of all large airways that possess cilia covered by a mucus gel layer with
maximum thickness of 5 µm in the trachea and to 0.5 µm in the bronchi [19]. There is a gradual
decrease in thickness of this layer, and 1.8 µm of lining fluid has been measured for human
bronchioles. It is likely that the mucus gel layer is not continuous and exposure to particles
might differ between cells [20]. Mucus and surfactant have different compositions; mucus
contains up to 95 % of water, followed by 2–3 % glycoproteins, 0.1–0.5 % proteoglycans, and
0.3–0.5 % lipids. Surfactant, on the other hand, consists of up to 90 % of lipids and 10 % of
proteins and therefore resembles more the composition of the human plasma membranes,
which on average contain 50 % lipid and 50 % protein [21]. The surfactant is not only reducing
the surface tension of the alveoli and preventing their collapse but presents also an effective
barrier against dehydration and invasion of pathogens.
2.2. Airway epithelium
The epithelium of the airways representing the main barrier for molecules and particles in
aerosols becomes thinner from the conducting (large) airways toward the alveoli, where gas
exchange takes place. In the large airways, the epithelium consists of columnar bronchial
epithelial cells with microvilli at their apical surface and goblet cells (Fig. 1). Smaller bronchi,
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bronchioles, have a cubic epithelium and secretory Clara cells, while alveoli are coated with a
squamous epithelium consisting of alveolar epithelial cell types I and II. Alveolar macrophages
migrate on the surface of this epithelium.
Figure 1. Barriers for particle uptake by the respiratory system. The mucus layer of the large bronchi can be divided in
the periciliary (PL) surrounding the cilia of the bronchial epithelial cells and the gel layer (GL). The epithelial layer of
the large (conducting) airways consists of columnar bronchial epithelial cells with cilia (BE) and mucus-producing
goblet cells (GC). In the bronchioli, cuboidal bronchial epithelial cells (BE) and mucus-producing Clara cells (C) are
found. All epithelial cells reside on a basement membrane (BM). The air–blood barrier at the alveolus consists of alveo‐
lar epithelial cell type I (AT-I) and surfactant-producing AT-II cells. Alveolar macrophages (M) migrate on top of the
alveolar epithelial cell layer. On the other side of the basement membrane, endothelial cells (EC) of capillaries are locat‐
ed.
Cytotoxicity testing is one of the first steps in the evaluation of toxicants and preclinical testing
of drugs. Cytotoxicity of conventional compounds is routinely studied after 4–48 h of exposure
because conventional toxicants either acutely damage cells or are degraded by the cell. In
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contrast to many conventional compounds, NPs have the ability to accumulate in cells and can
cause cellular effects also after longer times, for instance, by interference with organelle
function. Both extent and effect of cellular accumulation of NPs are currently largely unknown.
Most likely these effects are both particle dependent (e.g., content of metal ions, solubility/
biodegradability) and cell dependent (expression of uptake routes, proliferation rate, intra‐
cellular location). The thickness of the mucus layer on top of intestinal cells can reach up to
900 µm, while respiratory cells are covered only by a mucus layer of 12 µm. Permeability of
the epidermis is low due to the formation of the stratum corneum. In addition to the lack of a
protective acellular layer, the turnover time of lung cells is slow. Cells of colon crypts are
completely renewed after 3–4 days, and cells of the epidermis need 39 days. In contrast to that,
after one year, only 7 % of alveolar cells are renewed [22-24]. This combination results in a
higher accumulation and a lower regenerative capacity. Accumulation of NPs upon chronic
inhalation has been shown, for instance, for titanium dioxide NPs applied to rats over 28 days
and three months [25].
In vitro studies could help to estimate the extent and the consequences of cellular accumulation
and classify NPs according to their potential for chronic effects. Such information could
decrease the amount of labor- and cost-intensive and ethically problematic animal studies. As
some defense mechanisms, particularly mucociliary clearance and clearance by the systemic
circulation, are lacking in cellular models, such studies might be a tool to identify NPs with a
low potential of accumulation and cytotoxicity and probably a lower need for chronic in vivo
testing.
3. Components of a representative chronic cytotoxicity model
In order to assess the effects of NP accumulation in a relevant way, the in vitro model has to
fulfill several requirements. The important biological parameters are 1) selection of the
appropriate cells, 2) physiologically relevant culture system, 3) appropriate NP exposure, 4)
demonstration of cellular uptake and accumulation, and 5) information on cell damage/
cytotoxicity (Fig. 2). For interpretation of the findings, changes in physicochemical properties
of particles have to be taken into account.
3.1. Selection of the appropriate cells
Cellular studies are performed with primary cells or with cell lines. Primary cells have to be
isolated from fresh tissues prior to the experiments. They retain many of the cell-specific
properties but have a limited life span in culture. Due to the reduced availability of fresh human
tissue, mainly rat or murine primary cells are used. In addition to potential inter-species
differences, quality (cell viability) and purity (contamination with other cells) of the prepara‐
tion may vary leading to low reproducibility of the experiments. In contrast to primary cells,
immortalized cells, cell lines, provide more reproducible results. Cell lines show a much slower
senescence rate and are termed “immortal.” Cell lines have different origins; they may arise
during transformation of tumors, due to the presence of a viral gene that partially deregulates
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the cell cycle, by introduction of telomerase and by fusion with cancer (myeloma) cells. The
negative side of immortalization is that cells lose several cell-specific functions. Telomerase
immortalized cells are currently believed to be the best way of immortalization because
relatively many cell-specific functions are still present but only few TERT-immortalized
bronchial epithelial cell lines are available by commercial suppliers, mainly by the American
Type Culture Collection (ATCC). As a general rule, the selection of one or the other types of
cell is based on the scientific question that should be addressed. Studies on cell-specific
functions are performed better in primary cells. Basic cellular processes, such as proliferation,
necrosis, and apoptosis, are generally studied in cell lines. Several cell lines have been
described as representative models for respiratory cells [26]. They differ in their ability to form
a tight intercellular barrier, expression of specific transporters, and secretion products typical
for the respective cells. A549 cells and NCI-H441 cells are derived from alveolar epithelial cells.
Although they do not form a monolayer with sufficient tightness, A549 cells show surfactant
production and have been used in numerous toxicity studies [27, 28]. NCI-H441 cells are the
preferred line for transport studies since they form polarized tight monolayers and express
organic cation transporters and P-glycoprotein. Cell lines derived from bronchial epithelium
comprise BEAS-2B, NuLi-1, 16HBE14o-, and Calu-3 cells. BEAS-2B cells lack tight junctions
and mucus production but express organic cation transporters. NuLi-1 cells have been
characterized to a lower extent and are rarely used although they form a tight monolayer.
16HBE14o- cells have the ability to form tight junctions and express a variety of transporters.
Their main disadvantage is that they do not show the desired phenotype when cultured at an
the air–liquid interface, the most physiologically relevant type of culture for cells of the
respiratory system.
Figure 2. Key parameters for physiologically relevant testing of chronic exposure of airway cells. One potential realiza‐
tion of the principle (a) is presented (b).
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Calu-3 cells have been described as the suitable model for pulmonary permeability studies [29]
with good correlation of permeability values with drug absorption from the rat lung in vivo
[30]. Calu-3 cells are derived from bronchial submucosal glands, which explains their ability
to produce airway surface liquid, mucins, and other immunological active substances [31].
When cultured on membranes at an air–liquid interface, they form cellular monolayers with
tightness and expression of membrane transporters similar to the situation in vivo. Calu-3 cells
show mucin-containing granules at the apical pole of the cell (e.g., [32]), but a mucus layer
covering the cells cannot be discerned. This problem is linked to the high solubility of mucus
in water. After fixation of the tissue and staining either with anti-mucin antibodies or with
alcian blue, no mucus layer can be discerned neither in native bronchial tissue nor in Calu-3
cells [33].
3.2. Culture conditions for respiratory cells
Culture at an air–liquid interface is required to provide the most physiologically relevant
exposure conditions. This culture method is characterized by supply of the cells with nutrients
only from the basal side. This is usually obtained by culturing the cells on membranes in
polystyrene housings. These inserts vary in membrane material and pore size and provide the
cells with enough support and nutrient supply to form a stable monolayer. Air–liquid interface
culture, where the apical part of the cell is exposed to air and not to medium, compared to
conventional culture is illustrated in Fig. 3. Respiratory cells cultured at an air–liquid interface
show increased differentiation resulting in production of mucus in Calu-3 cells and surfactant
in A549 cells [34, 35].
Figure 3. Different ways of culture: Cell grown at the bottom of well and exposed to NPs suspended in medium (a). In
culture at an air–liquid interface, cells are grown on membranes and supplied with nutrients from the basal side. In
this culture, respiratory cells secrete pulmonary surfactant (blue line). Cells are exposed to NPs applied as aerosols (b).
AC: alveolar cell.
For the testing of particle effects after prolonged exposure, a constant cell population is desired.
Routine cell culture systems are less ideal because cells on plastic surfaces proliferate faster
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than cells in the human body, and intracellularly located NPs are diluted to a greater extent
than in vivo. In addition, the high proliferation rate makes compensation of minimal damage
possible. Fast proliferation in the culture system has another disadvantage in the evaluation
by physiology-based assays used for cytotoxicity testing. All results are normalized to the data
of the untreated control cells. This normalization poses the problem that if the untreated cells
show physiological growth inhibition due to high cell densities, cell damage by NP could be
overlooked.
In  order  to  prevent  nonphysiologically  high  proliferation  rates,  physiologically  relevant
culture systems have been developed. Culture in a polar environment, such as growth on
microspheres  and  on  membranes,  slows  down proliferation.  Three-dimensional  systems
such as hanging drops and seeding in hydrogels, on microspheres, and on other scaffolds
have been developed. These systems are suitable for several types of cells but do not provide
adequate  conditions  for  respiratory  cells  because  cells  are  cultured  submerged.  An
adaptation of the hanging drop method, however, has been developed and validated for
evaluation of gaseous toxicants up to 20 days [36]. Cell culture on membrane inserts, which
has been developed to study active and passive transport mechanisms of compounds across
cell monolayers, appears suitable. A microfluidic system has been adapted in a way that
culture on transwells at an air–liquid interface is possible and A549 cells cultured that way
maintained differentiation and viability for 14 days [37]. It is, however, not clear whether
under these culture conditions a stable monolayer of cells is obtained since some research
groups report multilayer formation of A549 cells in air–liquid interface culture already after
three days,  while other studies observed A549 monolayers for up to four weeks of  air–
liquid interface culture [38]. Also 16HBE14o- cells start the formation of multilayers after
17 days in this culture. One hypothesis for the formation of multilayers was absence of cell
removal from the apical side by medium changes. Calu-3 bronchial epithelial cells in air-
liquid interface  culture  appear  to  be  suitable  because  transepithelial  electrical  resistance
(TEER) values remain constant  for  17 days [39],  while  the most  often used Caco-2 cells
maintain constant values for a maximum of seven days.
3.3. Exposure with particles
Several methods have been used to expose cells to aerosols either as dry powders or by
nebulization of solutions. Deposition by aerosols results in a heterogeneous distribution
pattern (e.g., [40]) not unlike the in vivo situation where also different densities of particle
deposition have been measured [41]. Several groups assessed the effects of environmental NPs
(diesel exhaust, smoke) in vitro using either diffusion chambers or more advanced devices in
static or dynamic exposure. Setups usually used exposures over 15–60 min, where the aerosol
is generated and cells are exposed in a humid atmosphere at physiological temperature (37
°C). Particle deposition in most of the systems is driven by sedimentation and diffusion. Only
few established systems, including electrostatic aerosol in vitro exposure system (EAVES) and
CULTEX® radial flow system, employ electrostatic precipitation. The Voisin chamber [42,
43], Minucell system [44, 45], Nano Aerosol Chamber In Vitro Toxicity [46, 47], biological
aerosol trigger [48], air–liquid interface cell exposure (ALICE) system [49-51], and electrostatic
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aerosol in vitro exposure system [52, 53] were developed by specific researcher groups. Other
systems, such as CULTEX® [54, 55], CULTEX® RFS, and VITROCELL® [56], are commercially
available. CULTEX® and VITROCELL® systems have been used in the testing of volatile
organic compounds, copper NPs, carbon NPs, zinc oxide NPs, gold NPs, polystyrene NPs,
cerium oxide NPs, and laser printer emission particles [44, 57-60]. ALICE system [49-51] and
VITROCELL/PARI BOY [61] have been used for aerosolization of NP-containing liquid
aerosols. The deposition rates by these devices showed considerable variations related to the
aerosolization technique. Related to the total aerosolized amount in nebulizers particle
deposition ranged between 0.037 % for aerosolized polystyrene particles/well in the VITRO‐
CELL/PARI BOY system, 0.157 % in the ALICE system [51], and 2.8 % in the optimized ALICE
CLOUD system [62]. These systems may also lead to particle-dependent differences in
deposition [61].
To avoid differences in delivery due to material properties, the use of manual devices, like the
ones developed for animal exposures, might be advantageous. Delivery by these devices is
easy to perform, less expensive, and technically less demanding and results in a higher relative
deposition (amount of particles on cells related to total amount aerosolized) than by the more
physiological setups mentioned before. Frequently used syringe-based devices are available
from Penn Century Ltd and deliver aerosols generated from dry powder or from suspensions.
MicroSprayer® IA-1C aerosolizer for liquid aerosols and DP-4 Dry Powder Insufflator™ for
powder aerosols have been used for intratracheal delivery of nanoparticles and occupational
and environmental toxicants to mice and rats [63-66]. Both devices have also been used in
cellular studies [35, 61, 67-74]. Particle sizes produced by DP-4 Dry Powder Insufflator™ were
linked to the respective sizes of the formulated or of the not-formulated powders [75] and are
roughly similar before and after aerosolization [76]. The high amount of material that has to
be applied is problematic for in vitro studies. The minimal amount is linked to the accuracy of
the analytical balance and can be 1 mg as the minimum. An additional problem represents the
potential cell damage due to application. When using different distances between tip of the
device and cell surface, an optimum distance, when no cell damage occurred, can be identified.
With aerosolization devices from suspensions, such as the MicroSprayer® IA-1C aerosolizer,
also small amounts of NPs can be applied and the system, therefore, is less dependent from
the material. These systems show less electrostatic interaction between particles and devices,
aggregation of particles, and hygroscopy that decrease reproducibility of the experiments. The
main disadvantage of the MicroSprayer® IA-1C aerosolizer is the generation of droplet in sizes
of 20 µm that under normal conditions cannot reach the deep lung.
4. Readout parameters
In order to correlate cytotoxicity and accumulation, particle parameters and cellular uptake of
the NPs have also to be determined.
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4.1. Particle stability
Stability of particles, including chemical stability as well as colloidal stability may change over
the incubation time. Chemical stability is changed by degradation and dissolution of the
particles, while colloidal stability is influenced by pH, ions, and macromolecules in the
biological fluid. Biodegradability is given for therapeutic aerosols, not for NP inhaled as air
pollution and at the workplace. Detection of degradation products is particle specific and
usually detected by mass spectrometry. Particle characterization includes changes in bulk
composition, in size and structure, and in surface composition, surface charge, electrophoretic
properties, surface hydrophobicity, and aggregation [77]. Changes in bulk composition are
measured by energy dispersive X-ray spectroscopy (EDS), inductively coupled plasma mass
spectrometry (ICP-MS), and combustion analysis (CA) but are less likely to show incubation-
dependent changes in biological systems. Particle imaging by transmission electron micro‐
scopy, scanning electron microscopy, and atomic force microscopy can identify changes in size
and structure. X-ray photoelectron spectroscopy (XPS), Brunauer–Emmett–Teller (BET)
method, atomic force microscopy (AFM), and laser-Doppler velocimetry (LDV) are common
techniques to characterize surface properties of NPs. Agglomeration can be followed by static
light scattering (SLS), photon correlation spectroscopy (PCS)/dynamic light scattering (DLS),
small-angle neutron scattering (SANS), and nanoparticle tracking analysis (NTS) [78].
The most important parameter that has to be monitored during prolonged incubation is
colloidal stability. Colloidal stability of electrostatically stabilized particles is relatively low
because the surface charges are neutralized by ions in the solution and particles prone to
agglomeration. Binding of macromolecules may cause complex changes in surface charge,
composition, and hydrophobicity and often results in particle agglomeration. Coating of the
NPs with hydrophilic bulky molecules, such as polyethylene glycol (PEG), prevents binding
of proteins and sterically hinders agglomeration. For instance, gold NPs with PEG coating are
stable in physiological solution for 2–15 days [79]. Capping with biocompatible bulky organic
molecules, such as serum albumin and starch, also stabilized silver NPs better than electrostatic
repulsion by citrate [80]. This coating is absent for unintentionally inhaled NPs from the
workplace and environment, which therefore shows lower colloidal stability. Depending on
the particle properties with longer incubation in cell culture medium, either the average size
of the agglomerates or the fraction of large aggregates increased [81].
4.2. Cellular uptake/accumulation
Colorimetric reading might lack sensitivity but in principle is useful for quantification.
Prussian blue staining, for instance, is an established technique for demonstration of cellular
uptake of iron oxide particles [82]. Uptake can either be performed on the single-cell level or
in the entire population of exposed cells with fluorometric reading and flow cytometry. Also
inductively coupled plasma mass spectrometry (ICP-MS) is used for this purpose [83].
Microscopy-based techniques, such as laser scan microscopy and transmission electron
microscopy, may be suitable to confirm intracellular localization but are too laborious for
quantification. Software programs, e.g., provided as ImageJ macro, could be used to analyze
data from more cells [84]. Systems based on transmission electron microscopy scanning, rapid
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scanning X-ray fluorescence microscopy, and NMR relaxometric techniques are more speci‐
alized techniques for quantification of intracellular NPs [85-87].
4.3. Cytotoxicity
The assessment of cytotoxicity commonly uses changes in physiology such as cell number,
membrane integrity, amount of DNA or protein, and metabolic activity as readout and
indicated as changes in viability. Signals that are obtained after treatment with samples are
referred to untreated or solvent-treated cells. Screening assays are usually followed by other
tests because decrease of viability can be the result of a variety of influences: depletion of
nutrients, interference with organelle function, changes in pH, disruption of membrane
integrity, induction of apoptosis, inhibition of proliferation, etc. When cells are cultured on
membranes and not in plates, also measurements of TEER values can be used to indicate cell
damage. A breakdown in TEER values can be caused by disruption of intercellular junctions
or by induction of cell death. Since no indicators are used in these measurements, TEER
measurements belong to the label-free detection techniques. A variety of other label-free assays
are used for cytotoxicity testing of NPs. They have the advantage that no dye can interfere
with cell metabolism or with the particles. NPs have been reported to interfere with conven‐
tional cell-based assays in various ways and cause false-positive and false-negative results [88,
89]. Interference of NPs with colorimetric, fluorometric, and luminescent readout is usually
identified by inclusion of additional controls and performance of more than one assay. The
majority of the aforementioned methods in acute cytotoxicity screening can also be used for
the assessment of long-term exposure.
5. Own exposure system
In order to fulfill the requirements for organ-typical testing of NP accumulation, an exposure
system based on Calu-3 cells has been developed, which is described in the following.
5.1. Particles accumulation in Calu-3
5.1.1. Methodology
Calu-3 cells were cultured on polyethylene terephthalate membranes with pore size of 3 µm
at an air–liquid interface and showed constant TEER values from the 10th day until the end of
the observation period, which was chosen at the 28th day (Fig. 4a). During the establishment
of the model, cultures with different amounts of liquid in the basal compartment were
characterized. When 1,500 µl was applied to the basal compartment, a pseudostratified
columnar but not completely stable epithelium was formed. It appeared that the cells did not
form a continuous monolayer but that at some locations also multilayers were formed. The
epithelium was not stable because, as has been already hypothesized by Lehmann et al.,
removal of the medium detached cells of the upper layer [38]. When only 500 µl was applied
to the basal chamber, the Calu-3 cells formed a stable simple columnar epithelium. The
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different morphology appears to be caused by different volumes that reached the apical
compartment resulting from hydrodynamic pressure of the fluid in the basal chamber. When
1,500 µl was applied to the basal compartment, the apical chamber contained about 250 µl of
fluid. At volumes of 500 µl in the basal chamber, only 50 µl liquid was collected from the apical
compartment.
Accumulation of 1.8 µg/cm2 and 9 µg/cm2 fluorescently labeled 20 nm carboxyl-functionalized
polystyrene particles was studied. Addition as suspension in 10 µl cell culture medium was
preferred to application as aerosol by MicroSprayer® IA-1C aerosolizer because data from
pilot experiments did not show differences between these application forms. Furthermore,
data were more reproducible upon application in small volume than with MicroSprayer®
IA-1C aerosolizer. Particles in cell culture medium measured 42 nm with zeta potential of -41
mV. Cells were incubated with the particles for seven days with medium changes in the basal
compartment every other day. After seven days, supernatants of cells were collected, cells were
rinsed in cell culture medium, TEER measured, and cells incubated with the same amount of
NPs for another seven days. This procedure was repeated up to a whole observation time of
28 days. Membranes with cells at each time point (7, 14, 21, 28 days) were subjected to
quantification and visualization of uptake. For quantification of cellular uptake, cells were
removed from the membrane by trypsin treatment and counted by electrochemical sensing
and cellular uptake determined by fluorescence plate reader. Cellular uptake was determined
using a standard curve produced from particle solutions diluted with cell culture medium
containing cells. This dilution medium was chosen to correct for interference like quenching
or autofluorescence by cells. Confocal images obtained by laser scan microscopy allowed
visualization of stratification of the Calu-3 cell layer as well as verification of intracellular
uptake. In addition, immunocytochemical detection of mucin 5AC was used to identify mucus
production of the cells.
5.1.2. Results
During the entire exposure time, no decrease in TEER values was noted, suggesting absence
of cell damage (Fig. 4a). Uptake of particles showed intercellular and regional differences (Fig.
4b). Over the entire observation time, Calu-3 cells formed a continuous monolayer, but not all
cells showed obvious staining with anti-mucin 5AC antibody as indication for mucus pro‐
duction. This situation resembles the in-vivo condition, where also a non continuous mucus
layer in the bronchi has been reported [20]. Cellular uptake of NPs was higher in cells with no
mucus production (Fig. 4c). For both concentrations of polystyrene particles, linear cellular
accumulation was noted (Fig. 4d).
5.2. Discussion of the presented model
Calu-3 cells were cultured on polyethylene terephthalate membranes with pore size of 3 µm.
These pores should allow the passage of the particles, but pilot experiments using naked
membranes showed that only a fraction of the carboxyl-functionalized polystyrene particles
(52 %) was detected on the other side of the membrane. Permeation of polystyrene particles
across 3 µm polycarbonate membranes has been reported differently; while one study
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Figure 4. Accumulation of 20 nm fluorescently labeled carboxyl-functionalized polystyrene particles (red) in Calu-3 cells
over 28 days. TEER values remained constant over the entire exposure time (a). Differences in accumulation of NPs be‐
tween cells are seen (b). In the volume-rendered 3-D reconstruction performed on the z-series of images at d28, accumula‐
tion of NPs mainly in cells showing no prominent anti-mucus production (anti-mucin 5AC staining; green) is seen. Arrow
indicates the membrane on which the Calu-3 cell monolayers were grown (c). Quantification of cellular uptake by fluoro‐
metric reading shows a linear accumulation of the particles over time (d). Doses of 1.8 µg/cm2 and 9 µg/cm2 were applied
and theoretical uptake (Theory) is extrapolated based on the uptake after seven days. Scale bar: 20 µm.
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recovered almost 100 % of 50 nm carboxyl-functionalized and plain polystyrene particles after
6 h [90], another group reported passage of about 25 % of 37 nm carboxyl-functionalized
polystyrene particles [91]. Low translocation rates after 24 h of incubation across the same
membranes are also reported for 50 nm silica NPs; more than 90 % of the applied particles
were trapped in the membranes [92]. These studies suggest that particle transport across
cellular monolayers may give erroneous data on cellular transport of polystyrene particles.
Growth of Calu-3 cells in air–liquid interface culture with different volume of medium in the
basal chamber could help in identifying differences between monolayered and multilayered
epithelium. However, the multilayers that were obtained when using a greater volume in the
basal chamber were less stable, and morphological variations and less constant TEER values
were obtained.
The currently used system is based on fluorescence labeling of the particles. This labeling may
cause changes in surface properties or size. For polystyrene particles, changes in surface
properties by fluorescence labeling can be excluded because the particles are synthesized and
subsequently swollen in organic fluid containing the dye. This is followed by gradient
evaporation of the solvent and repeated washing of the particles to remove dye from the
surface [93]. Any fluorescent labeling mode, however, bears also the problem of stability
because loss of the label may reduce the measured accumulation values when freshly prepared
solutions are used for preparation of the standard curve. The advantage of the polystyrene
particles that were used in this study is that they showed stable fluorescence over the entire
incubation time of 28 days. Preparation of the standard curves using stock solutions, which
are kept under the same conditions as for the cellular exposures, may be more appropriate. It
is, however, not excluded that the dilution influences stability since fluorescently labeled
particles are more stable in concentrated than in diluted solution (https://www.bdbioscien‐
ces.com/documents/BD_Accuri_SPHERO_RainbowCalibration_Particles_ProdInfoSh‐
eet.pdf). In addition, stability may be different for intracellular- and extracellular-located
particles. Degradation of the label by intracellular enzymes might be expected to reduce the
stability of the fluorescence of intracellularly located particles.
The estimate of NP uptake in this study was based on particle uptake after seven days; this
uptake could be the result of an inhibited uptake already at that time. Sequential exposure to
different NPs and measurement at shorter time points than seven days could be used to answer
the question whether the presence of intracellular particles affects the uptake of new particles.
The type of intracellular localization/accumulation may influence cellular effects. Most NPs
are taken up by endocytotic mechanisms that deliver their content to lysosomes. Studies on
correlation of intralysosomal and extralysosomal accumulation to cell damage may provide
further information.
In the concentration range tested, no obvious inhibition of particle uptake was seen, suggesting
that cells can handle these particle concentrations without obvious damage. For the identifi‐
cation of potential threshold values and mechanistic studies, exposure to higher concentrations
of NPs has to be performed. In addition to that, studies on other particle sizes may provide
further insight into cellular effect of inhaled NPs.
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In addition to cytotoxicity, exposure to NPs may induce inflammation and including cytokine
release as readout parameter may identify this effect. Secretion of the cytokines interleukin-6
and interleukin-8 has been used as an indication for inflammatory response in Calu-3 cells [94].
Co-culture of alveolar epithelial cells with macrophages could provide more insight into the
interplay of different cell types at the alveolar barrier. It is questionable that both cell types can
be observed over longer periods because of the different medium requirements and prolifer‐
ation rates.
6. Conclusion
Chronic cytotoxicity testing of respiratory cells is linked to specific problems. Only few cells
tolerate air–liquid interface culture for a prolonged time and without change in morphology.
Exposure to aerosol may present particle-dependent delivery rates. The presented exposure
system fulfilled all requirements for physiologically relevant testing of prolonged contact to
NPs by respiratory exposure. Doses that were applied in the model are in the same order of
magnitude as therapeutic aerosols [95]. The data showed relatively low inhibition of particle
uptake by intracellularly accumulated NPs. Study of particle transport is limited by the fact
that insert membrane do not allow unimpeded passage of the particles.
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